SCHEMBL10224901

SCHEMBL10224901

CCCc1cc(CC)cc(C)n1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 2/20 0.46
NOS3 P29474 1/20 0.46
NOS1 P29475 1/20 0.46
CTSK P43235 2/20 0.39
CTSS P25774 1/20 0.39
BACE1 P56817 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
MAPT P10636 3/20 0.37
KDM5B Q9UGL1 1/20 0.37
KDM4E B2RXH2 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CYP1A2 P05177 1/20 0.35
SREBF2 Q12772 2/20 0.35
ALDH1A1 P00352 1/20 0.34
ATM Q13315 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16548415 0.89 NOS2 (0.47) NOS2NOS3NOS1CTSKCTSS
SCHEMBL10730571 0.87 NOS3 (0.47) NOS2NOS3NOS1CTSKCTSS
SCHEMBL7129717 0.85 NOS3 (0.43) NOS2NOS3NOS1NPC1RAB9A
SCHEMBL13264050 0.80 NPC1 (0.33) NPC1RAB9AMAPTCYP1A2ATM
SCHEMBL805463 0.79 NPC1 (0.45) NOS2NOS3NOS1NPC1RAB9A
SCHEMBL17932864 0.79 NPC1 (0.37) NOS2NOS3NOS1NPC1RAB9A
SCHEMBL11829782 0.78 NOS2 (0.64) NOS2NOS3NOS1BACE1MAPT
SCHEMBL13550177 0.78 NOS3 (0.40) NOS2NOS3NOS1CTSKCTSS
SCHEMBL11732278 0.76 PTGS2 (0.47) NOS2NPC1RAB9AL3MBTL1
SCHEMBL20356746 0.76 KDM5A (0.33) NOS2NOS3NOS1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178743-A1 NOVEL ADENINE COMPOUND AND USE THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-12 US disclosed
US-8148371-B2 Adenine compound and use thereof DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-04-03 US disclosed
US-20100256118-A1 NOVEL ADENINE COMPOUND AND USE THEREOF DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256118-A1 NOVEL ADENINE COMPOUND AND USE THEREOF ADORA1, P2RY10, HRH4 NOS2 930/4885NOS3 1369/4885NOS1 610/4885
US-20120178743-A1 NOVEL ADENINE COMPOUND AND USE THEREOF ADORA1, HRH4, P2RY10 NOS2 681/4885NOS3 1042/4885NOS1 452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.